ACE OncoCast

Updates on Oncogene-Driven NSCLC from Vienna: Osimertinib resistance

August 14, 2022 ACE Oncology Season 4 Episode 3
ACE OncoCast
Updates on Oncogene-Driven NSCLC from Vienna: Osimertinib resistance
Show Notes

In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechanisms to osimertinib and emerging strategies to overcome resistance.